Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Dydrogesterone). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Divanor is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Progesterone deficiencies: Threatened miscarriage: 40 mg (four tablets) at once, then 10 mg (one tablet) every eight hours until symptoms remit. Habitual miscarriage: 10 mg (one tablet) twice daily until the twentieth week of pregnancy. Dysmenorrhoea: 10 mg (one tablet) twice daily from day 5 to day 25 of the menstrual cycle. Endometriosis: 10 mg (one tablet) two or three times daily from day 5 to day 25 of the cycle or continuously. Dysfunctional bleeding (to arrest bleeding): 10 mg (one tablet) twice daily for five to seven days. Presentation should be given with oestrogen. Dysfunctional bleeding (to prevent bleeding): 10 mg (one tablet) twice daily from day 11 to day 25 of the cycle. Presentation should be given with oestrogen. Amenorrhoea: An oestrogen once daily from day 1 to day 25 of the cycle, together with 10 mg Presentation twice daily from day 11 to day 25 of the cycle. Irregular cycles: 10 mg (one tablet) twice daily from day 11 to day 25 of the cycle. Infertility due to luteal insufficiency: 10 mg (one tablet) daily from day 14 to day 25 of the cycle. The treatment should be continued for at least 6 consecutive cycles. It is advisable to continue this treatment during the first month of any pregnancy using the doses stated with respect to habitual miscarriage. Luteal support as part of an Assisted Reproductive Technology (ART) treatment: 10 mg three times daily (three tablets daily) starting at the day of oocyte retrieval and continuing for 10 weeks if pregnancy is confirmed. Hormone Replacement Therapy: In combination with continuous oestrogentherapy, take one tablet daily for 14 consecutive days of a 28 day cycle. In combination with cyclical oestrogen therapy take one tablet daily during the last 12 to 14 days of oestrogen therapy. For doctors: If endometrial biopsies or ultrasound reveal inadequate Presentationational response, 20 mg Dydrogesterone should be prescribed. For patients: If you are not sure what type of oestrogen therapy you are on, talk to your Doctor before taking Presentation. There is no relevant use of Dydrogesterone before menarche. The safety and efficacy of Dydrogesterone in adolescents aged 12 to 18 years has not been established.
Side Effects
The most commonly reported side effects in patients taking Caryon during clinical trials for indications not involving oestrogen treatment include migraines/headaches, nausea, menstrual disorders, and breast pain or tenderness.
Cautions & Contraindications
Warnings & Precautions
Before starting Caryon for abnormal bleeding, the cause of the bleeding should be clarified first. Breakthrough bleeding and spotting may occur during the first few months of treatment. If breakthrough bleeding or spotting shows up after some time on therapy, or continues after treatment has been stopped, the reason should be investigated, which may include an endometrial biopsy to rule out endometrial malignancy. If any of the following conditions occurs for the first time or worsens during use, stopping treatment should be considered: severe headache or migraine, or symptoms suggesting cerebral ischemia; a marked rise in blood pressure; or the occurrence of venous thromboembolism (VTE). In cases of habitual or threatened miscarriage, the viability of the fetus should be confirmed, and it is also necessary to monitor during treatment whether the pregnancy is still progressing and whether the embryo remains alive. Treatment with Caryon has occasionally been associated with changes in liver function, sometimes with accompanying clinical symptoms, so it should be used with caution in patients with acute liver disease or a history of liver disease until liver function tests return to normal, and in cases of severe hepatic impairment, treatment should be stopped. Patients with a history of depression should be monitored closely, and if severe depression returns, treatment with Caryon should be discontinued.
Contraindications
Hypersensitivity to the active substance or to any of the excipients. Known or suspected progestogen-dependent tumours. Unexplained vaginal bleeding of undiagnosed cause. Use for preventing endometrial hyperplasia in women taking oestrogen therapy. Thrombophlebitis or other thromboembolic disorders. Cerebrovascular or coronary artery disease, whether current or a past history of these. Liver disease or impaired liver function, including a history of cholestatic jaundice, pruritus of pregnancy, Dubin-Johnson syndrome, or Rotor syndrome. A history of herpes occurring during pregnancy. Sickle cell anaemia. Benign or malignant liver tumours that developed during previous use of oral contraceptives.